torcetrapib has been researched along with aldosterone in 14 studies
| Studies (torcetrapib) | Trials (torcetrapib) | Recent Studies (post-2010) (torcetrapib) | Studies (aldosterone) | Trials (aldosterone) | Recent Studies (post-2010) (aldosterone) |
|---|---|---|---|---|---|
| 273 | 28 | 83 | 25,333 | 1,517 | 4,169 |
| Protein | Taxonomy | torcetrapib (IC50) | aldosterone (IC50) |
|---|---|---|---|
| Mineralocorticoid receptor | Homo sapiens (human) | 0.0048 | |
| Mineralocorticoid receptor | Rattus norvegicus (Norway rat) | 0.043 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chapman, MJ; Guérin, M; Kontush, A | 1 |
| Dullaart, RP; Kobold, AC; van Tol, A | 1 |
| Hegele, RA; Joy, TR | 1 |
| Bloomfield, D; Briscoe, RJ; Brown, PN; Cumiskey, AM; Ehrhart, J; Forrest, MJ; Hershey, JC; Keller, WJ; Ma, X; McPherson, HE; Messina, E; Peterson, LB; Sharif-Rodriguez, W; Siegl, PK; Sinclair, PJ; Sparrow, CP; Stevenson, AS; Sun, SY; Tsai, C; Vargas, H; Walker, M; West, SH; White, V; Woltmann, RF | 1 |
| Dietz, JD; Hu, X; Keiser, J; Knight, DR; Loging, WT; Perry, DA; Smith, AH; Xia, C; Yuan, H | 1 |
| Bamberger, M; Betts, A; Blasi, E; Engwall, M; John-Baptiste, A; Keiser, J; Knight, D; Winter, S; Wolk, R | 1 |
| Burnier, M; Vogt, B | 1 |
| Stroes, ES; Vergeer, M | 1 |
| Funder, JW | 2 |
| Bénardeau, A; Capponi, AM; Clerc, RG; Funder, JW; Garriz, JM; Hainaut, E; Hoflack, JC; Niesor, EJ; Perez, A; Pflieger, P; Stauffer, A; Weibel, F | 1 |
| Ambler, CM; Chang, GC; Clark, RW; Francone, O; Frederick, KS; Garigipati, RS; Hatch, HL; Hu, X; Kalgutkar, AS; Lefker, BA; Morehouse, LA; Perry, DA | 1 |
| Even, S; Montezano, AC; Neves, KB; Nguyen Dinh Cat, A; Palacios, R; Rios, FJ; Touyz, RM | 1 |
| DeLisle, RK; Ganz, P; Hyde, C; Malarstig, A; Murthy, AC; Ostroff, R; Segal, MR; Weiss, SJ; Williams, SA | 1 |
5 review(s) available for torcetrapib and aldosterone
| Article | Year |
|---|---|
Spotlight on HDL-raising therapies: insights from the torcetrapib trials.
Topics: Aldosterone; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Dyslipidemias; Humans; Hypertension; Quinolines | 2008 |
Aldosterone and cardiovascular risk.
Topics: Aldosterone; Antihypertensive Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Humans; Hyperaldosteronism; Kidney Diseases; Metabolic Syndrome; Obesity; Quinolines | 2009 |
The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
Topics: Aldosterone; Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Blood Pressure; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Corticosterone; Esters; Humans; Hydrocortisone; Hypercholesterolemia; Oxazolidinones; Quinolines; Sulfhydryl Compounds | 2009 |
Aldosterone, sodium, and hypertension: lessons from torcetrapib?
Topics: Aldosterone; Animals; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Humans; Hypercholesterolemia; Hypertension; Quinolines; Sensitivity and Specificity; Sodium | 2010 |
Aldosterone, hypertension and heart failure: insights from clinical trials.
Topics: Aldosterone; Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Dihydrotestosterone; Drug Therapy, Combination; Enzyme Inhibitors; Female; Heart Failure; Heptanoic Acids; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Mice; Mineralocorticoid Receptor Antagonists; Ouabain; Pyrroles; Quinolines; Rats; Spironolactone | 2010 |
2 trial(s) available for torcetrapib and aldosterone
| Article | Year |
|---|---|
Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.
Topics: Adolescent; Adult; Aldosterone; Animals; Anticholesteremic Agents; Blood Pressure; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Rate; Humans; Macaca fascicularis; Male; Middle Aged; Quinolines; Renin-Angiotensin System; Tandem Mass Spectrometry; Young Adult | 2009 |
Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Topics: Aged; Aldosterone; Anticholesteremic Agents; Biomarkers, Pharmacological; Case-Control Studies; Cholesterol Ester Transfer Proteins; Drug-Related Side Effects and Adverse Reactions; Early Diagnosis; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Prospective Studies; Proteomics; Quinolines; Stroke; Survival Analysis | 2018 |
7 other study(ies) available for torcetrapib and aldosterone
| Article | Year |
|---|---|
Torcetrapib and coronary events.
Topics: Aldosterone; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Female; Humans; Linear Models; Male; Middle Aged; Quinolines | 2008 |
The failure of torcetrapib: what have we learned?
Topics: Aldosterone; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Humans; Hyperaldosteronism; Oxazolidinones; Quinolines | 2008 |
Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.
Topics: Adrenal Cortex; Aldosterone; Animals; Anticholesteremic Agents; Blood Pressure; Cholesterol Ester Transfer Proteins; Corticosterone; Dogs; Drug Evaluation, Preclinical; Female; Macaca mulatta; Male; Mice; Mice, Inbred C57BL; Models, Animal; Muscle, Smooth, Vascular; Oxazolidinones; Quinolines; Rats; Rats, Sprague-Dawley; Species Specificity | 2008 |
Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition.
Topics: Adrenal Gland Neoplasms; Aldosterone; Anticholesteremic Agents; Blood Pressure; Calcium Signaling; Carcinoma; Cell Line, Tumor; Cholesterol Ester Transfer Proteins; Cytochrome P-450 CYP11B2; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Humans; Hydrocortisone; Intracellular Fluid; Models, Biological; Quinolines; Steroid 11-beta-Hydroxylase; Structure-Activity Relationship | 2009 |
Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.
Topics: Adrenal Cortex; Adrenal Gland Neoplasms; Aldosterone; Amides; Angiotensin II; Animals; Anticholesteremic Agents; Blood Pressure; Calcium; Calcium Channels, L-Type; Cell Line, Tumor; Cholesterol Ester Transfer Proteins; Cytochrome P-450 CYP11B2; Cytosol; Enzyme Induction; Esters; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Gene Expression Profiling; Humans; Hypertension; NAV1.1 Voltage-Gated Sodium Channel; Nerve Tissue Proteins; Quinolines; Rats; Rats, Inbred SHR; RNA, Small Interfering; Sodium Channels; Structure-Activity Relationship; Sulfhydryl Compounds | 2010 |
Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
Topics: Administration, Oral; Aldosterone; Animals; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cytochrome P-450 CYP3A Inhibitors; Drug Design; Drug Evaluation, Preclinical; Female; Humans; Injections, Intravenous; Isonipecotic Acids; Macaca fascicularis; Male; Microsomes, Liver; Quinolines; Rats, Sprague-Dawley; Solubility; Structure-Activity Relationship | 2014 |
Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
Topics: Adipocytes; Aldosterone; Amides; Animals; Cell Line; Cholesterol Ester Transfer Proteins; Esters; Humans; Mice; NADPH Oxidases; Oxazolidinones; Phosphorylation; Quinolines; Reactive Oxygen Species; STAT3 Transcription Factor; Sulfhydryl Compounds | 2015 |